Pediatrix Q2 FY26 EPS rises 6.52% to $0.49; net revenue increases 4% to $488 million

• Pediatrix Medical Group posted Q2 earnings of $0.49 per share, up from $0.46 a year earlier.
• Net income edged up to $40 million, while net revenue rose 4% to $488 million versus the prior-year quarter.
• Adjusted EBITDA increased to $76 million; adjusted EPS climbed to $0.63 from $0.53.
• Same-unit reimbursement-related factors rose 4%, while same-unit patient volume fell 2.1% with NICU days down 3.2%.
• CEO Mark S. Ordan cited favorable acquisition trends and reimbursement metrics; full-year adjusted EBITDA outlook reaffirmed at $280 million-$300 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pediatrix Medical Group Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804235421) on August 04, 2026, and is solely responsible for the information contained therein.